Literature DB >> 16279140

Translational clinical trials: an entropy-based approach to sample size.

Steven Piantadosi1.   

Abstract

Translational clinical trials are small studies of therapies emerging from the laboratory. These trials are essential for generating early evidence regarding the effects of treatment on specific targets in the disease pathway and for guiding the next studies to be done. The statistical properties of such studies have been neglected, in part, because they do not fit the well-known clinical trials developmental paradigm. This paper discusses the translational trial setting, and presents an information (entropy) based approach to understanding the properties and use of these trials. The combination of biological knowledge with a designed experiment (albeit a small one) is a powerful device for resolving much of the considerable uncertainty surrounding an emerging therapeutic concept. An approach to motivating the sample size for translational trials is presented.

Mesh:

Year:  2005        PMID: 16279140     DOI: 10.1191/1740774505cn078oa

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  12 in total

1.  First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study.

Authors:  Veronica Marchetti; Mario Giorgi; Anna Fioravanti; Riccardo Finotello; Simonetta Citi; Bastianina Canu; Paola Orlandi; Teresa Di Desidero; Romano Danesi; Guido Bocci
Journal:  Invest New Drugs       Date:  2011-04-21       Impact factor: 3.850

2.  A Prospective Cohort Study of Neural Progenitor Cell-Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Patients With Glioblastoma.

Authors:  Chengcheng Gui; Tracy D Vannorsdall; Lawrence R Kleinberg; Ryan Assadi; Joseph A Moore; Chen Hu; Alfredo Quiñones-Hinojosa; Kristin J Redmond
Journal:  Neurosurgery       Date:  2020-07-01       Impact factor: 4.654

3.  EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.

Authors:  Fotios Loupakis; Chiara Cremolini; Anna Fioravanti; Paola Orlandi; Lisa Salvatore; Gianluca Masi; Marta Schirripa; Teresa Di Desidero; Carlotta Antoniotti; Bastianina Canu; Pinuccia Faviana; Elisa Sensi; Cristiana Lupi; Gabriella Fontanini; Fulvio Basolo; Antonello Di Paolo; Romano Danesi; Alfredo Falcone; Guido Bocci
Journal:  Target Oncol       Date:  2013-07-03       Impact factor: 4.493

4.  A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma.

Authors:  Anna R Damato; Ruth G N Katumba; Jingqin Luo; Himachandana Atluri; Grayson R Talcott; Ashwin Govindan; Emily A Slat; Katherine N Weilbaecher; Yu Tao; Jiayi Huang; Omar H Butt; George Ansstas; Tanner M Johanns; Milan G Chheda; Erik D Herzog; Joshua B Rubin; Jian L Campian
Journal:  Neurooncol Pract       Date:  2022-01-31

5.  Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.

Authors:  Jiayi Huang; Jian L Campian; Amit D Gujar; Christina Tsien; George Ansstas; David D Tran; Todd A DeWees; A Craig Lockhart; Albert H Kim
Journal:  J Neurooncol       Date:  2018-01-27       Impact factor: 4.130

Review 6.  Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.

Authors:  James Isaacs; Aaron C Tan; Brent A Hanks; Xiaofei Wang; Kouros Owzar; James E Herndon; Scott J Antonia; Steven Piantadosi; Mustafa Khasraw
Journal:  Clin Cancer Res       Date:  2021-07-26       Impact factor: 12.531

7.  Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.

Authors:  F Loupakis; C Cremolini; A Fioravanti; P Orlandi; L Salvatore; G Masi; T Di Desidero; B Canu; M Schirripa; P Frumento; A Di Paolo; R Danesi; A Falcone; G Bocci
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

8.  Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma.

Authors:  Emanuela Fina; Andrea Necchi; Patrizia Giannatempo; Maurizio Colecchia; Daniele Raggi; Maria Grazia Daidone; Vera Cappelletti
Journal:  Bladder Cancer       Date:  2016-10-27

Review 9.  Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Authors:  Brian P Hobbs; Pedro C Barata; Yada Kanjanapan; Channing J Paller; Jane Perlmutter; Gregory R Pond; Tatiana M Prowell; Eric H Rubin; Lesley K Seymour; Nolan A Wages; Timothy A Yap; David Feltquate; Elizabeth Garrett-Mayer; William Grossman; David S Hong; S Percy Ivy; Lillian L Siu; Steven A Reeves; Gary L Rosner
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

10.  A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

Authors:  G Allegrini; A Falcone; A Fioravanti; M T Barletta; P Orlandi; F Loupakis; E Cerri; G Masi; A Di Paolo; R S Kerbel; R Danesi; M Del Tacca; G Bocci
Journal:  Br J Cancer       Date:  2008-03-25       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.